IVF In Animals Market Generated Opportunities, Future Scope
Coherent Market Insights has published a report titled "IVF In Animals Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033". The report details market competition, geographic distribution, growth potential, industry performance, and key success factors. Leading players include Zoetis, Merck Animal Health, and Elanco Animal Health, with segmentation covering various animal types.
Perrigo Co PLC (MEX:PRGO) Stock Price, Trades & News
This GuruFocus article provides a detailed stock analysis of Perrigo Co PLC (MEX:PRGO), a consumer health company. It covers key financial metrics, warning signs, growth and profitability ranks, dividend information, and upcoming investor events, including earnings dates and past press releases. The company primarily sells private-label consumer health goods in North America and national brands in Europe, Australia, and parts of Asia.
Is Strong Q2 Results And Portfolio Shift Altering The Investment Case For Phibro Animal Health (PAHC)?
Phibro Animal Health reported strong fiscal Q2 2026 results, exceeding revenue and earnings expectations, and demonstrating improved profitability. The company's integration of Zoetis' medicated feed additive business and an expanding vaccines franchise are shifting its product mix towards higher-value items and broader international reach, potentially reshaping its investment narrative due to accelerating earnings and margin trends. While the outlook is positive, with revenue projected to reach $1.5 billion and earnings $119.1 million by 2028, investor caution is advised regarding its fair value and potential overreliance on medicated feed additives.
(ZTS) and the Role of Price-Sensitive Allocations
This article provides an AI-generated analysis of Zoetis Inc. Class A (NYSE: ZTS), highlighting neutral stability in shorter time horizons but continued weakness long-term. It details specific trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis indicating support and resistance levels. The report emphasizes the role of price-sensitive allocations in managing risk for ZTS.
ImmuCell (NASDAQ: ICCC) boosts 2025 margins, shifts from Re‑Tain to core First Defense calf-health line
ImmuCell Corporation reported a strategic shift in 2025, moving its focus from the Re-Tain product to its core First Defense calf-health line. This pivot led to improved gross margins, rising from 30% to 41% of product sales, and a narrowed net loss of $1.0 million, despite a $2.7 million non-cash impairment charge related to Re-Tain assets. The company also increased its First Defense manufacturing capacity to 4.6 million units and plans further expansion, aiming to capitalize on the growing calf scours prevention market.
Price to cash flow ratio of Zoetis, Inc. Class A – BSESOF:ZOE
The article serves as a financial data page from TradingView, focusing on the Price to cash flow ratio for Zoetis, Inc. Class A (BSESOF:ZOE). It shows the market status as closed with no trades, and provides navigation to different financial aspects of the company like financials, news, and technicals. The main content indicates a display for the price to cash flow ratio, period, value, and change, although the actual numerical data is not present in the provided text.
Quick ratio of Zoetis, Inc. Class A – BSESOF:ZOE
This article provides the quick ratio for Zoetis, Inc. Class A (BSESOF:ZOE). It focuses on financial data for the company, accessible through TradingView. The page emphasizes market data and financial metrics for investors.
Companion Animal Health Market Forecast 2026-2033 Featuring Strategic Analysis of Agrolabo, Boehringer Ingelheim, Ceva, Elanco, IDEXX Labs and More
The global companion animal health market is projected to grow from USD 25.46 billion in 2025 to USD 56.41 billion by 2033, exhibiting a CAGR of 10.6%. This growth is attributed to advancements in therapeutics and diagnostics, increased awareness of zoonotic diseases, and evolving regulatory frameworks. The report provides a comprehensive analysis including market segmentation by animal, product, distribution channel, and end-use, alongside profiles of key industry players.
Zoetis, Inc. Class A Trade Ideas — BSESOF:ZOE
This page on TradingView presents various trade ideas and technical analyses for Zoetis, Inc. Class A (BSESOF: ZOE, NYSE: ZTS). Different traders offer bullish and bearish outlooks, including long-term holds, shorting strategies, and short-term trading opportunities based on earnings, technical indicators, and chart patterns. The analyses provide specific entry and exit points, risk-to-reward ratios, and detailed descriptions of the methodologies used.
Zoetis, Inc. Class A Trade Ideas — BSESOF:ZOE
This article compiles various trade ideas for Zoetis, Inc. (ZOE), highlighting its strong fundamentals, growth opportunities in the animal health industry, and potential for recovery after a recent stock price decline. Multiple analysts and traders suggest long positions, citing technical indicators like support levels, capitulation signals, and projected price targets ranging from $169.96 to $300, despite some short-term risks identified.
Vanguard disaggregates holdings; reports 0% stake in Zoetis (ZTS)
The Vanguard Group has filed an amended Schedule 13G/A for Zoetis Inc. (ZTS), reporting a 0% beneficial ownership stake. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report their holdings separately, as per SEC Release No. 34-39538. The filing indicates that The Vanguard Group itself no longer holds beneficial ownership of Zoetis shares, with future reporting expected from its disaggregated subsidiaries.
Animal Vaccines Market Set to Boom Rapidly by 2033 | Merck & Co.,
The Animal Vaccines Market is projected for rapid growth between 2026 and 2033, driven by innovation, investment, and shifting regional dynamics. A new report by Coherent Market Insights provides key insights, segmentation by Type, Application, and Region, and actionable intelligence to help stakeholders navigate market opportunities. Top companies in this sector include Merck & Co. Inc., Boehringer Ingelheim International GmbH., and Zoetis Inc.
First Merchants Corp Has $1.98 Million Holdings in Zoetis Inc. $ZTS
First Merchants Corp significantly reduced its stake in Zoetis Inc. by 42% in Q4, liquidating 11,387 shares and retaining 15,707 shares valued at approximately $1.98 million. Despite this reduction, other institutional investors, including CIBC Asset Management and Mitsubishi UFJ Trust, increased their holdings in Zoetis. Analysts have a mixed outlook for ZTS, with a consensus "Hold" rating and an average price target of $152.91, although some firms like BTIG and Morgan Stanley forecast targets up to $160, and Goldman Sachs has upgraded it to a "Buy."
Latest PAWZ ETF News Today | Earnings, Events & Price Alerts
This page provides the latest news, earnings, events, and price alerts for the PAWZ ETF. It features a collection of recent articles related to pet care companies like Chewy, Zoetis, Petco Health, and Freshpet, discussing topics such as e-commerce trends, AI initiatives, stock performance, and analyst ratings. The content aims to keep investors informed on the pet care sector.
AI Investing Insights - Official Homepage - Intellectia AI™
This page provides an overview of the PAWZ ETF, detailing its investment strategy, current price information, and asset composition. The fund focuses on companies benefiting from pet ownership, with 99.66% of its assets in stocks and 0.34% in cash. Although specific financial figures are listed as 0.000, it outlines the fund's profile and top holdings.
Dominion Energy’s $65 Billion Capital Plan Supports a $91 Bull Case
Dominion Energy's increased capital plan of $64.7 billion, driven by surging data center demand in Virginia, is expected to boost its EPS to $4.63 by 2030, supporting a $91 bull case according to TIKR's valuation model. Despite some near-term Street caution, the company's long-term EPS growth target of 5% to 7% is underpinned by contracted data center capacity and strategic projects like the Coastal Virginia Offshore Wind. Investors are advised to examine TIKR's data for a comprehensive understanding of the stock's potential.
JPMorgan Chase & Co. Has $32.06 Million Stock Position in Allison Transmission Holdings, Inc. $ALSN
JPMorgan Chase & Co. increased its holdings in Allison Transmission Holdings, Inc. (NYSE:ALSN) by 6.5% during the third quarter, bringing its total to 377,739 shares valued at approximately $32.06 million. Analysts have a "Hold" consensus rating with a $112.00 price target, though individual targets vary and some firms have raised their outlooks. Allison Transmission also recently increased its quarterly dividend to $0.29 per share, resulting in an annualized yield of about 1.0%.
Q&A: The gap between AI ambitions and data readiness
Ataccama CEO Mike McKee discusses the disconnect between high AI ambitions and the reality of organizations' data readiness. He highlights that while AI is rapidly advancing, many businesses struggle with data governance, connecting AI investments to ROI, and fundamental data management, often mistaking people and process problems for technological ones. McKee emphasizes the need for a solid data foundation, business-aligned initiatives, and more usable, unified platforms to bridge this gap.
OCUL Stock Price, Quote & Chart | OCULAR THERAPEUTIX INC (NASDAQ:OCUL)
This article provides a detailed overview of Ocular Therapeutix Inc. (NASDAQ: OCUL), including its current stock price, performance metrics, key statistics, and financial data. It highlights the company's technical and fundamental ratings from ChartMill, its earnings history, and analyst forecasts. The company's profile, biopharmaceutical focus, and pipeline products like AXPAXLI, DEXTENZA, and PAXTRAVA are also described.
Pricier vet care: Fewer visits but still many $11,000 surgeries
Despite a decline in routine vet visits, pet owners are still spending significant amounts on emergency and critical care for their animals, leading to continued growth in animal health companies' earnings. This trend is attributed to the increasing humanization of pets, where owners view them as family members and are willing to incur high costs for their well-being, even for surgeries costing thousands of dollars. Companies like IDEXX Laboratories, Zoetis Inc., Elanco Animal Health Inc., Petco Health & Wellness Co., and Chewy Inc. are benefiting from this consistent spending on premium pet care.
Responsive Playbooks and the ZTS Inflection
This article analyzes Zoetis Inc. (NYSE: ZTS), indicating a near-term neutral sentiment with mid and long-term weakness. It highlights an exceptional short setup with a 32.5:1 risk-reward ratio and provides three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) based on AI models, alongside multi-timeframe signal analysis for support and resistance levels.
New Mexico Educational Retirement Board Invests $2 Million in Elanco Animal Health Incorporated $ELAN
The New Mexico Educational Retirement Board recently acquired 99,200 shares, valued at approximately $1.998 million, of Elanco Animal Health Incorporated ($ELAN) in the third quarter, indicating renewed institutional interest. Several analysts have upgraded their ratings for Elanco, resulting in a "Moderate Buy" consensus and an average target price of $27.67. Elanco also reported strong Q3 earnings, beating analyst estimates with an EPS of $0.13 and revenue of $1.14 billion, and provided positive FY2026 guidance.
There’s Still Hope for This Struggling Concentrated Growth Fund
Polen Growth (POLRX), a concentrated growth fund, has underperformed its benchmark and peers for several years due to market headwinds, portfolio concentration issues, and stock-picking errors, particularly missing out on high-flying tech stocks. Despite these struggles, the article argues that the fund's strong management team, disciplined investment process focusing on quality companies, and recent adjustments to their strategy offer hope for future improved performance.
Will Westlake Corp. (WLK) Benefit from Housing Market Recovery?
Diamond Hill Capital's "Mid Strategy" Q4 2025 investor letter highlighted Westlake Corporation (WLK) as a new addition, expecting its chemical and building products segments to benefit from a housing market recovery. Despite Westlake not being among the top 40 most popular stocks for hedge funds, the strategy believes the company, a low-cost chemicals producer, is well-positioned for long-term growth as current supply-side headwinds in its commodity businesses are managed. The firm suggests AI stocks may offer higher and quicker returns for those seeking such opportunities.
Phibro Insider Moves Shift Class Structure As Stock Trades Near Highs
Phibro Animal Health Corporation is experiencing shifts in its class structure as an insider, Jack Bendheim, sold Class A shares under a pre-arranged plan, and BFI Co., LLC converted Class B shares to Class A. These moves affect insider holdings, voting rights, and the mix of share classes, occurring as the stock trades near 52-week highs following strong fiscal Q2 2026 results. The article discusses potential implications for governance, liquidity, and investor sentiment, noting that while some see these as ordinary portfolio adjustments, they also signal a lean towards more institutional ownership and a slight reduction in super-voting stock power.
Zoetis falls 3.6% as investors reassess 2026 growth outlook and recent precision-animal-health acquisition
Zoetis (ZTS) stock fell 3.6% after investors reassessed its 2026 growth outlook and recent acquisition. The decline appears to be driven by caution regarding near-term growth in companion-animal franchises and a recent $160 million acquisition of Neogen’s animal genomics business. The company had previously issued full-year 2026 guidance and has been returning capital to shareholders through repurchases and dividends.
Animal Health Market size to reach $199.1 Billion by 2035 | Key
The animal health market is projected to grow from approximately $70.7 billion in 2025 to $199.1 billion by 2035, driven by evolving farming practices, veterinary services, and consumer preferences. North America is expected to dominate, while Asia Pacific will see the fastest growth. Key trends include digitalization, the rise of companion animal care, and a focus on preventive healthcare, with major players like Zoetis and Merck Animal Health making strategic advancements.
ZTS SEC Filings - Zoetis Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Zoetis Inc. (ZTS) SEC filings, including 10-K, 10-Q, and 8-K reports, along with insider trading forms. It details recent material events like the completion of a private offering of convertible senior notes, the issuance of other senior notes, and revolving credit agreements. The platform also offers AI-powered tools to summarize key terms and highlights important disclosures for investors.
Cinctive Capital Management LP Reduces Holdings in Elanco Animal Health Incorporated $ELAN
Cinctive Capital Management LP significantly reduced its stake in Elanco Animal Health Incorporated by 53.8% in the third quarter of 2025, selling 137,675 shares and retaining 118,239 shares valued at $2.38 million. Despite this reduction from one hedge fund, other institutional investors like Primecap Management Co. CA, Vanguard Group Inc., Dimensional Fund Advisors LP, UBS Group AG, and Brandes Investment Partners LP increased their holdings in Elanco Animal Health, which now has an average rating of "Moderate Buy" from analysts. The company reported earnings above consensus and has positive financial guidance for Q1 and FY 2026.
Ameriprise Financial Inc. Grows Position in Zoetis Inc. $ZTS
Ameriprise Financial Inc. increased its stake in Zoetis Inc. by 3.5% in the third quarter, now owning 0.75% of the company. Several other institutional investors also adjusted their positions in ZTS. Analysts have issued varied ratings, with a consensus "Hold" and an average target price of $152.91, while Zoetis reported beating earnings estimates and declared a quarterly dividend.
Is Zoetis Inc. (ZTS) A Good Stock To Buy Now?
This article summarizes a bullish thesis from Rebound Capital on Zoetis Inc. (ZTS), highlighting its leadership in the animal health market, strong companion animal and livestock segments, and projected 2025 revenue. Despite recent stock depreciation and concerns over its osteoarthritis drug Librela, the company's deep pipeline and innovation suggest a compelling long-term investment opportunity. However, the article notes that Zoetis is not among the 40 most popular stocks among hedge funds, and suggests other AI stocks may offer higher and quicker returns.
Antero Midstream Corp Stock (ISIN: US03674X1063) Hits New Highs Amid Marcellus Expansion
Antero Midstream Corp (ISIN: US03674X1063) has reached new 52-week highs following a transformative US$1.1 billion acquisition in the Marcellus Shale, significantly boosting its 2026 guidance for adjusted EBITDA and free cash flow after dividends. The strategic deal integrates more closely with Antero Resources' production and expands fee-based revenues, attracting investor attention and analyst recommendations. The company's strong financial health, low leverage, and consistent dividend yield reinforce its position as a stable midstream play in the energy sector.
Private Management Group Inc. Cuts Stock Position in Elanco Animal Health Incorporated $ELAN
Private Management Group Inc. significantly reduced its stake in Elanco Animal Health by 37.5% in the third quarter of 2025, selling over 965,000 shares. Despite this, analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $27.67, driven by strong Q3 earnings that surpassed expectations. The company also provided optimistic guidance for fiscal year 2026.
A Look At Phibro Animal Health (PAHC) Valuation After A Strong 1 Year Total Return
Phibro Animal Health (PAHC) has seen a 135.9% total return over the past year, with revenues of US$1.46 billion and net income of US$92.09 million. While a popular narrative suggests the company is slightly overvalued at $48.50 due to non-repeatable growth drivers, a discounted cash flow model suggests it is significantly undervalued at $119.16. Investors are faced with conflicting valuation views, prompting a closer look at the company's future cash generation and growth prospects.
Schroder Investment Management Group Has $24.09 Million Stock Position in Hershey Company (The) $HSY
Schroder Investment Management Group increased its stake in Hershey Company (HSY) by 5.1% to 128,774 shares, valued at $24.09 million. Other institutional investors like Vanguard and JPMorgan also added to their positions, bringing total institutional ownership to nearly 58%. Despite recent insider selling, strong Q4 earnings, positive guidance for FY2026, and a dividend increase, analysts maintain a "Hold" rating on Hershey.
Zoetis Backs Vet Tech Training To Deepen Long Term Clinic Ties
Zoetis (NYSE:ZTS) is expanding its support for veterinary education by offering free Human Animal Bond Certification to veterinary technician students across the US, a move aimed at deepening long-term clinic ties and influencing practice standards. This initiative is seen as a strategic way for Zoetis to embed itself in daily clinic workflows and reinforce its leadership in animal health, even though the financial benefits may not be immediately measurable. Investors are encouraged to monitor how management links this program to clinic adoption and customer engagement, and how competitors respond.
CreativeOne Wealth LLC Reduces Stake in Innovator U.S. Equity Power Buffer ETF – May $PMAY
CreativeOne Wealth LLC reduced its stake in Innovator U.S. Equity Power Buffer ETF – May (PMAY) by 23.9% in the 3rd quarter, selling 14,093 shares and holding 44,918 shares. Despite this reduction, other institutional investors like Alliancebernstein L.P., Penserra Capital Management LLC, Raymond James Financial Inc., Osaic Holdings Inc., and Cetera Investment Advisers increased their positions in the ETF. The Innovator U.S. Equity Power Buffer ETF – May (PMAY) aims for specific buffered losses and capped gains on the S&P 500 Index.
Understanding the Setup: (ZTS) and Scalable Risk
This article analyzes Zoetis Inc. Class A (NYSE: ZTS), highlighting weak sentiment across all time horizons which supports a short bias. It outlines a mid-channel oscillation pattern and offers three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles. The analysis points to an exceptional 32.2:1 risk-reward short setup targeting a 9.3% downside against a 0.3% risk.
Valaris Limited $VAL Shares Purchased by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP increased its stake in Valaris Limited (NYSE:VAL) by 8.2% in the third quarter, now owning 3,028,408 shares valued at $147.7 million. Despite institutional ownership of nearly 97%, analysts have a cautious "Reduce" rating with a consensus price target of $56.50, reflecting recent downgrades. Valaris, an offshore drilling services provider, currently trades around $90.96 with a market cap of $6.3 billion and a PE ratio of 6.5.
IDEXX Laboratories Stock: Here’s Why Wall Street Sets $750 Mean Target
IDEXX Laboratories (IDXX) exceeded Q4 expectations with $1.09 billion in revenue, driven by strong performance from its inVue Dx analyzer. The company’s innovative pipeline, share repurchase program, and EPS growth algorithm position it for continued success despite potential challenges in clinic visit declines. Wall Street analysts have a mean price target of $750.23, implying significant upside, while TIKR's model suggests an even higher fair value of $998.68.
Capital International Sarl Sells 7,255 Shares of Electronic Arts Inc. $EA
Capital International Sarl reduced its stake in Electronic Arts (NASDAQ:EA) by 4.1% in the third quarter, selling 7,255 shares and now owning 168,398 shares valued at $33.97 million. Other institutional investors have also adjusted their holdings in EA. The article also details recent insider sales by Vijayanthimala Singh and CEO Andrew Wilson, and provides an overview of EA's financial metrics and analyst ratings, which show a consensus "Hold" rating with an average price target of $188.30.
Citigroup Inc. Cuts Stake in Elanco Animal Health Incorporated $ELAN
Citigroup Inc. significantly reduced its stake in Elanco Animal Health Incorporated by 75.5% in the third quarter of 2025, selling 344,563 shares and leaving it with 112,058 shares valued at $2.26 million. Despite this, company insiders, including Director Lawrence Kurzius and CEO Jeffrey N. Simmons, increased their holdings through recent stock purchases. Elanco Animal Health recently surpassed EPS and revenue estimates and holds a "Moderate Buy" consensus rating with a target price of $27.67.
Zoetis to acquire Neogen Corp. genomics business
Zoetis Inc. is set to acquire Neogen Corp.'s animal genomics business for $160 million, with the deal expected to close in the second half of 2026. Neogen, a leader in U.S. beef and dairy genomics, plans to use the proceeds for debt reduction and to focus on its core food and animal safety businesses. This acquisition aligns with Zoetis' strategy to expand its Precision Animal Health business and enhance livestock innovation through genomics.
Cooper-Standard (NYSE:CPS) Shares Cross Below 200 Day Moving Average - Here's Why
Cooper-Standard Holdings Inc. (NYSE:CPS) stock recently fell below its 200-day moving average, trading at $33.56 against a 200-day MA of $34.25, indicating a technical sell signal. Analysts hold a mixed outlook with an average "Hold" rating and a $43.33 price target, despite the company missing quarterly EPS estimates but exceeding revenue expectations. Institutional investors and hedge funds have shown increased interest, collectively owning approximately 69% of the shares.
Steven Klinsky Buys 250,495 Shares of New Mountain Finance (NASDAQ:NMFC) Stock
Director Steven Klinsky has purchased 250,495 shares of New Mountain Finance (NASDAQ:NMFC) for approximately $1.99 million, increasing his stake to 4,754,338 shares. Despite a quarterly dividend implying a 15.8% yield, the company's dividend payout ratio is an unsustainably high 853.33%. Analysts have a "Reduce" rating on NMFC with an average price target of $9.25, and institutional investors have also adjusted their positions in the company.
Deutsche Raises its Price Target on Banco Bilbao Vizcaya Argentaria, S.A. (BBVA) to EUR 21.24 and Maintains a Buy Rating
Deutsche Bank has increased its price target for Banco Bilbao Vizcaya Argentaria, S.A. (BBVA) to EUR 21.24 from EUR 19.75, reaffirming a Buy rating due to improved net interest income and higher return on tangible equity forecasts. This follows recent adjustments by other banks, with RBC Capital also raising its price target while changing its rating to Sector Perform, and Morgan Stanley slightly lowering its target but maintaining an Equal Weight rating. The article also touches on BBVA's diverse banking and financial services across multiple regions and suggests exploring AI stocks for higher upside potential.
Injected Veterinary Pain Management Drugs Market Set to Witness Rapid Growth Through 2033 | Zoetis Inc., Elanco Animal Health Incorporated
Coherent Market Insights has released a detailed report on the "Injected Veterinary Pain Management Drugs Market," forecasting rapid growth through 2033. The report provides an in-depth analysis of market trends, challenges, opportunities, competitive dynamics, and regional performance, featuring key players like Zoetis Inc. and Elanco Animal Health Incorporated. It aims to serve as a crucial decision-support tool for industry stakeholders, covering critical success factors, risk assessment, and financial analysis.
Integrated Quantitative Investments LLC Takes $1.34 Million Position in United Natural Foods, Inc. $UNFI
Integrated Quantitative Investments LLC has acquired a new position in United Natural Foods, Inc. (UNFI), purchasing 35,685 shares worth approximately $1.34 million in the third quarter, representing about 0.06% of the company. Institutional investors collectively own 87.63% of UNFI, while insiders hold 2.40%, with recent insider transactions including a director buying shares and another insider selling shares. Analysts currently have an average "Hold" rating for UNFI with a mean price target of $38.78.
Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks
This article reviews the Q4 earnings performance of several branded pharmaceutical companies, highlighting Bristol-Myers Squibb (BMY), Eli Lilly (LLY), Corcept (CORT), Supernus Pharmaceuticals (SUPN), and Zoetis (ZTS). While the sector as a whole had mixed results, with revenues generally missing estimates, Bristol-Myers Squibb and Eli Lilly posted strong revenue beats. Corcept, however, significantly missed analyst expectations for revenue and EPS.
Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks
Bristol-Myers Squibb (NYSE:BMY) and other branded pharmaceutical companies recently reported their Q4 earnings. While the industry faces headwinds like regulatory scrutiny and patent cliffs, Bristol-Myers Squibb and Eli Lilly showed strong revenue growth, exceeding analyst expectations. Corcept and Zoetis also reported results, with Corcept missing revenue estimates and Zoetis beating expectations for revenue and EPS.
